European Equities Close Mixed in Monday Trading; BBVA Raises Offer to Buy Sabadell to $20 Billion

12:10 PM EDT, 09/22/2025 (MT Newswires) -- European stock markets opened the week mixed in Monday trading as the Stoxx Europe 600 edged 0.13% lower, Germany's DAX declined 0.48%, the FTSE 100 gained 0.11%, France's CAC was off 0.3%, and the Swiss Market Index increased 0.14%.

The European Commission's Economic Sentiment Indicator for September rose 0.5 percentage points and 0.6 points in the EU and euro area, respectively, according to the European Commission's Directorate-General for Economic and Financial Affairs, which said the consumer confidence has remained "markedly below" its historical average since April.

In corporate news, Banco Bilbao Vizcaya Argentaria (BBVA) said Monday that it has raised its offer to acquire Banco Sabadell by 10% to 17 billion euros ($20 billion).

Under the new bid, BBVA will offer one share for every 4.8376 Banco Sabadell shares, valuing Banco Sabadell shares at 3.39 euros apiece.

Shares of Banco Bilbao Vizcaya Argentaria lost 2.44%, while Banco Sabadell's stock fell close to 4% in Madrid trading.

Stellantis said Sunday it detected unauthorized access to a third-party service provider's platform that supports Stellantis' North American customer service operations. Stellantis said the data breach exposed contact information and did not involve financial data or other sensitive personal details.

Shares of Stellantis fell 2.6% in Paris.

Automotive stocks were the biggest losers on the German market after Porsche AG delayed its electric vehicle model rollout and slashed its 2025 profitability forecast.

Citing weak demand, the German automaker said the delays would impact its 2025 operating profit by up to 1.8 billion euros. As a result, the company cut its return on sales forecast to slightly positive to 2% from the previously guided 5% to 7%.

Shares of Porsche AG dropped 4.65% in Frankfurt.

BP has halted development of a planned standalone biofuels facility at its Rotterdam refinery in the Netherlands, Reuters reported Monday, citing a company spokesperson. The oil giant's decision comes amid the latest in a series of scrapped projects as oil majors scale back renewable fuel ambitions amid soft demand, according to the report.

Shares of the British oil and gas company were up nearly 1% on the FTSE 100 in London

AstraZeneca said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of Koselugo in the European Union to treat neurofibromatosis type 1.

The UK pharmaceutical company said the decision was based on a phase 3 trial that showed "a statistically significant objective response rate."

Shares of AstraZeneca gained 1.7% in London.

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.